GDF-15 IS ASSOCIATED WITH FUNCTIONAL CAPACITY & VENTRICULAR DYSFUNCTION IN PATIENTS WITH MODERATE TO SEVERE AORTIC STENOSIS & PRESERVED EJECTION FRACTION
Lauren Basmadjian(Montreal Heart Institute), Christine Henri(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Raymond Cartier(Montreal Heart Institute), François Simard(Montreal Heart Institute), Jean‐François Dorval(Montreal Heart Institute), Nadia Bouabdallaoui(Montreal Heart Institute), Martin G. Sirois(Montreal Heart Institute), Jessica Forcillo(Montreal Heart Institute), Raoul Bonan(Montreal Heart Institute), Réda Ibrahim(Université de Montréal), Anique Ducharme(Montreal Heart Institute), Ismaı̈l El-Hamamsy(Mount Sinai Hospital), Anita Asgar(Montreal Heart Institute)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k
Percutaneous Aortic Valve Replacement for Severe Aortic Stenosis in High-Risk Patients Using the Second- and Current Third-Generation Self-Expanding CoreValve Prosthesis
|Journal of the American College of Cardiology|2007|947
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
|New England Journal of Medicine|2013|918